CMAJ • November 7, 2006; 175 (10). doi:10.1503/cmaj.051637.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vickers, D.
Right arrow Articles by Shah, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vickers, D.
Right arrow Articles by Shah, S.
Related Collections
Right arrow Other infectious diseases
Right arrow Drugs: immunological products and vaccines
Right arrow Vaccination
Right arrowRelated Article

Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children

David Vickers, Allen G. Ross, Raúl C. Mainar-Jaime, Cordell Neudorf and Syed Shah

From the Department of Applied Research (Vickers [at the time of submission]), College of Medicine, University of Saskatchewan; the Saskatoon Regional Health Authority (Ross, Neudorf); the Department of Community Health and Epidemiology (Ross, Shah), College of Medicine, University of Saskatchewan; and the Department of Microbiology (Mainar-Jaime), Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Sask.


Figure 116
View larger version (25K):

[in a new window]
  		Fig. 1: Age-specific incidence of pertussis (per 10 000 population) among children less than 10 years old in Saskatoon Regional Health Authority (1995–2005), by age group.

 

Figure 216
View larger version (25K):

[in a new window]
  		Fig. 2: Age-specific incidence of pertussis (per 10 000 population) among children less than 10 years old in Saskatoon Regional Health Authority, by birth cohort (each year represents the year in which members of the cohort were < 1 year old). *The absolute incidence of pertussis at age 3 years for the cohort born in 2000 (data not shown) was estimated to be 32.2 per 10 000 population.

 

View this table:

[in a new window]
  		Table 1.

 

Figure 316
View larger version (16K):

[in a new window]
  		Fig. 3: Effect of vaccine type on the incidence of pertussis among children aged < 1 year, 1–4 years and 5–9 years. Note: wP = whole-cell pertussis vaccine, aP = acellular pertussis vaccine, wP/aP = combination of both vaccines. (*Because of a high variance estimate, the rate ratio for the wP/aP vaccine group has not been interpreted and has only been included to maintain continuity in the figure.)